Last reviewed · How we verify
NCT06144333: CEB Covid-19
Collection of Additional Biological Samples From Potentially COVID-19 Patients for Monitoring of Biological Parameters Carried Out as Part of the Routine
NA trial testing RIPH2 in SARS CoV 2 Infection in 7,500 participants. Not yet recruiting.
10 December 2025
Quick facts
| Lead sponsor | CerbaXpert |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 7,500 |
| Start date | 23 December 2024 |
| Primary completion | 10 December 2025 |
| Estimated completion | 23 November 2026 |
Drugs / interventions tested
- RIPH2
Conditions studied
- SARS CoV 2 Infection — all drugs for SARS CoV 2 Infection →
Sponsor
CerbaXpert
Who can join
18 and older, any sex, with SARS CoV 2 Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients infected with SARS-CoV-2 can present with a wide range of manifestations clinical conditions, ranging from no symptoms to serious or chronic illness. The current gold standard test for the diagnosis of COVID-19 is based on a molecular test of reverse transcription polymerase chain reaction (RT-PCR), aimed at detecting the RNA of the virus in respiratory samples such as nasopharyngeal swabs or aspirates bronchial, other methods such as antigen tests and serological detection tests IgM and IgG in response to COVID-19 viral infection, can be used for the purposes of screening in the general population. In this context of variety of existing tests, it is important to monitor the biological parameters related to COVID-19 pathology by tracking the accuracy, specificity and sensitivity of these tests in current clinical practice. This research is a collection of additional biological samples with minimal impact on the intake usual care of the patients concerned, for the monitoring of biological parameters carried out in routine on several reagent kits used for screening for the SARS-CoV-2 virus, in terms of sensitivity, specificity, positive and negative predictive values, for the implementation of indicators quality monitoring of these kits.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06144333
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SARS CoV 2 Infection
Currently open trials in the same condition.
- NCT07189936 — Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS · Phase 2 · recruiting
- NCT07197164 — Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients · Phase 2 · recruiting
- NCT06950177 — Pancoronavirus Vaccine Study in Healthy Adults · Phase 1 · active not recruiting
- NCT06640387 — CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools · recruiting
- NCT06633835 — Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United St · Phase 4 · active not recruiting
Other CerbaXpert trials
Trials by the same sponsor.
- NCT05983679 — Prevalence of Sexually Transmitted Infections (STIs) and Coinfections in the General Population · not yet recruiting
- NCT06623058 — Accupower ® HCV Performance Evaluation Quant Kit Bioneer Existation™FA 96/384 · not yet recruiting
- NCT06623071 — Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96/384 · recruiting
- NCT06373510 — Longitudinal Evaluation of Antibody Kinetics of Vaccinated Patients With Non-mandatory Vaccine Following Administration · NA · not yet recruiting
- NCT06159257 — Evaluation of the Physiological Stability Variability and Robustness of NIS4 · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06144333 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CerbaXpert
- Last refreshed: 15 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06144333.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing